Genentech hedge(hog)s its bets

When Biogen Inc. ended its deal with Curis Inc. to discover and commercialize proteins of the hedgehog gene family in neurological indications, BGEN cited its uncertainty about when a compound could reach the clinic. BGEN's concerns were not totally unjustified, as

Read the full 413 word article

How to gain access

Continue reading with a
two-week free trial.